Amgen (NASDAQ:AMGN) recently presented additional data on its oncology candidate, blinatumomab (AMG 103). The company presented results from a phase II single-arm dose-ranging study which showed that 72% of patients achieved a high rate of complete response (CR).
The study was conducted in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL). The most common adverse events observed in patients who received the selected dose and schedule included pyrexia (70%), … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards